Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02584569 · ClinicalTrials.gov registry record · Phase 1
Phase 1 TAK-915 Single-Dose Positron Emission Tomography (PET) Occupancy Study
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02584569 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 12 participants.
The verdict
NCT02584569, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This phase 1 study will be conducted to examine the degree and duration of brain PDE2A enzyme occupancy /target engagement as a function of TAK-915 plasma concentration in order to guide dosing and schedule for future clinical studies in schizophrenia with TAK-915.
Interventions
- DRUG TAK-915
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02584569
The ClinicalTrials.gov registry entry for NCT02584569 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAK-915 is the first listed.
NCT02584569 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02584569 about?
NCT02584569 is a clinical study titled "Phase 1 TAK-915 Single-Dose Positron Emission Tomography (PET) Occupancy Study". This phase 1 study will be conducted to examine the degree and duration of brain PDE2A enzyme occupancy /target engagement as a function of TAK-915 plasma concentration in order to guide dosing and schedule for future clinical studies in schizophrenia with TAK-915.
What is the current status of trial NCT02584569?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2015-11. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02584569?
The interventions under investigation include: TAK-915 (DRUG).
Who is sponsoring clinical trial NCT02584569?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.